Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a drug called idelalisib (formerly known as GS-1101 or
CAL-101) as a possible treatment for Waldenstrom's Macroglobulinemia (WM).